araag2/HINT huggingface dataset:
Clinical trial NCT00064753 (phase 2/phase 3, status: completed)
Conditions: chronic kidney disease, cardiovascular disease, death
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0, A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30, G93.82, P01.6, Z63.4, Z82.41, O36.4XX1, O36.4XX2, O36.4XX3
Drugs: high dose multivitamin
SMILES: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Eligibility criteria:

        Inclusion Criteria:

          -  35 - 75 years old

          -  Had kidney transplant at least 6 months

          -  Calculated Creatinine Clearance must be 25 mL/min or greater

          -  Must be willing to stop supplements (B6, B12, folic acid) for 4-6 weeks prior to visit

        Exclusion Criteria:

          -  If pregnant or lactating

          -  If of child bearing potential and not on birth control

          -  If any of the following will limit life expectancy to less than 2 yrs:

               -  Cancer

               -  Congestive heart failure (CHF) (end stage)

               -  Liver disease (end stage)

               -  Severe pulmonary disease

               -  Progressive HIV

               -  Any other chronic wasting illness

          -  If patient had myocardial infarction (MI), stroke, lower extremity amputation above
             ankle or percutaneous revascularization procedure (coronary, cerebrovascular, lower
             extremity) in past 2months

          -  If patient had coronary artery bypass graft (CABG) or abdominal aortic aneurysm (AAA)
             in past 5 months

          -  If patient has conditions that prevent reliable study participation e.g., depression,
             alcohol or drug abuse, other cardiovascular disease (CVD) studies

          -  If patient has had multi-organ transplant, except kidney/pancreas
Clinical trial NCT01359150 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cp-690,550, placebo
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The subject must meet the American College of Rheumatology (ACR) classification
             criteria for the diagnosis of RA by satisfying at least four of the seven criteria.

          -  The subject must have active disease at both screening and baseline

        Exclusion Criteria:

          -  History of any documented influenza or pneumococcal infection within the last 3
             months.

          -  Receipt of any vaccine within 1 month prior to the initial study drug administration
             (CP-690,550 or placebo CP-690,550).

          -  If a subject has received an influenza vaccine within 6 months or a pneumococcal
             vaccine within 5 years of initial study drug administration.
Clinical trial NCT00505492 (phase 2, status: terminated)
Conditions: uterine neoplasms
ICD codes: C57.4, D28.2
Drugs: carboplatin, cisplatin, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with histologically confirmed malignant mixed mesodermal (MMMT) confined to
             the pelvis (Stage IB, IC, IIA, IIB, IIIA).

          -  Patients who have undergone a total abdominal hysterectomy, vaginal hysterectomy or
             laparoscopic assisted vaginal hysterectomy and a bilateral salpino-oophorectomy (with
             minimal surgical staging, including omental biopsy and lymph node sampling) within 8
             weeks of study entry.

          -  No known metastatic extrauterine metastases, no known gross residual disease or
             distant metastases.

          -  Women of any racial or ethnic group are eligible.

          -  Zubrod performance status of </= 2.

          -  Adequate bone marrow, renal and hepatic function: Hgb > 10 gm/dl, ANC >1.5/mm3,
             Platelets > 100,000/mcl, Creatinine < 1.5 mg/%, Bilirubin < 2.5 mg/dl, SGPT < 2* ULN,
             BUN < 1.5* ULN.

          -  No prior chemotherapy or radiation therapy for this diagnosis.

          -  Estimated life expectancy of 12 weeks or greater.

          -  Must sign an institutionally approved informed consent.

        Exclusion Criteria:

          -  Previously treated malignant mixed mesodermal (MMMT) with either chemotherapy or
             radiotherapy (XRT)/

          -  Patients with gross residual disease, suspected extrapelvic or extrauterine disease or
             distant metastatic disease (Stage IIIB, IIIC or IV).

          -  History of other malignancy, with the exception of non-melanomatous skin cancer,
             unless in complete remission and off all therapy for that disease for a minimum of 5
             years.

          -  Patients with a Zubrod performance status of 3 or greater.

          -  Patients with an active systemic infection.

          -  Patients with a serious intercurrent medical illness.

          -  Patients with a recent (within 6 months) history of cardiac dysrhythmia, congestive
             heart failure, unstable angina or myocardial infarction.
Clinical trial NCT00497159 (phase 2, status: completed)
Conditions: huntington's disease
ICD codes: G10
Drugs: dimebon
SMILES: CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical features of HD and a confirmatory family history of HD, and/or genetically
             confirmed HD;

          -  Able to take medication (capsules) by mouth.

        Exclusion Criteria:

          -  Clinical evidence of unstable medical illness;

          -  Females who are pregnant or lactating or who intend to become pregnant during the
             study period.
Clinical trial NCT00316238 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: olanzapine-raim, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have schizophrenia that meets disease diagnostic criteria in DSM-IV-TR

          -  Patients must be inpatients during the study

          -  Patients must have a minimum total score of no less than 14 on the five items of the
             PANSS-EC and at least one individual item score of no less than 4 using the 1-7
             scoring system prior to the first injection of study drug

        Exclusion Criteria:

          -  Patients who have a known history of diabetes mellitus.

          -  Patients who have received treatment with antipsychotics or other prohibited
             concomitant medicines within 2 hours prior to the first IM study drug administration

          -  Patients who have had treatment with benzodiazepines within 4 hours prior to first IM
             study drug administration.
Clinical trial NCT00234442 (phase 2, status: terminated)
Conditions: brain neoplasms, non small cell lung cancer
ICD codes: C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, D49.6, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: iressa (gefitinib)
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Reason stopped: 
    closed due to insufficient recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Radiologically confirmed brain metastases from Non Small Cell Lung Cancer

          -  No symptoms due to brain metastases

          -  No previous radiotherapy treatment for the Brain metastases

        Exclusion Criteria:

          -  No prior chemotherapy

          -  No other co-existing malignancies or malignancies diagnosed within the last 5 years
             with the exception of basal cell carcinoma or cervical cancer in situ

          -  Any evidence of severe or uncontrolled systemic disease (e.g., unstable or
             uncompensated respiratory, cardiac, hepatic, or renal disease)
Clinical trial NCT00113321 (phase 2, status: terminated)
Conditions: myelodysplastic syndrome, chronic myelomonocytic leukemia
ICD codes: D46.9, D46.C, D46.Z, C93.11, C93.12, C93.10
Drugs: decitabine
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. MDS and 5% or more marrow blasts, or IPSS risk intermediate 1-2 or high risk; or
             chronic myelomonocytic leukemia. Patients must have failed therapy with azacytidine.

          2. Performance status 0-2 (ECOG scale); adequate hepatic (bilirubin < 2 mg/dl) and renal
             functions (creatinine <2mg/dl); New York Heart Association (NYHA)cardiac status III-IV
             excluded.

          3. Signed informed consent.

          4. No prior intensive combination chemotherapy or high-dose ara-C (>/= 1g/m*2 per dose).
             Prior biologic therapies, targeted therapies and single agent chemotherapy allowed.

          5. Patients must have been off chemotherapy for 2 weeks prior to entering this study and
             recovered from the toxic effects of that therapy, unless there is evidence of rapidly
             progressive disease. Use of hydroxyurea for patients with rapidly proliferative
             disease is allowed for the first two weeks on therapy.

        Exclusion Criteria:

          1. Nursing and pregnant females are excluded. Patients of childbearing potential should
             practice effective methods of contraception. Should a woman become pregnant or suspect
             she is pregnant while participating in this study, she should inform her treating
             physician immediately.

          2. Patients with active and uncontrolled infections.

          3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, or
             psychiatric illness/social situations that would limit compliance with study
             requirements.
Clinical trial NCT00510224 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: sandostatin
SMILES: [H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]
Reason stopped: 
    stopped at interim analyses phase due to lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate.

          -  Biochemical disease progression following androgen deprivation and therapy with at
             least one antiandrogen defined as three rises in PSA with PSA determinations at least
             4 weeks apart and each PSA value > 0.2 ng/ml.

          -  Four weeks since prior therapy with Flutamide.

          -  Six weeks since prior therapy with Bicalutamide or Nilutamide.

          -  Current PSA > 5 ng/ml.

          -  Testosterone <50 ng/dL.

          -  SGPT (ALT) < 1.5 times upper limit of normal.

          -  Fasting blood glucose > 60 mg/dL.

          -  ECOG performance status 0, 1 or 2.

          -  No visceral or bony metastatic disease (Lymph node only metastases are allowed).

          -  No prior chemotherapy for prostate cancer.

          -  No current treatment with insulin or an oral hypoglycemic.

          -  No history of treatment with octreotide analogs for prostate cancer.

          -  No NYHA Class 3 or 4 cardiac status.

        Exclusion Criteria:

          -  Diabetes Mellitus requiring medical therapy and/or that which is not controlled by
             dietary means (HbA1C<6.0).

          -  A history of gallstones that has been clinically significant. Patients who have
             undergone cholecystectomy are eligible.

          -  Other concomitant medical or psychiatric condition which would make it undesirable, in
             the physician's opinion, for the patient to participate in the protocol or would
             jeopardize compliance with the protocol requirements.

          -  Prior treatment with chemotherapy for prostate cancer.

          -  No current treatment with Saw Palmetto, or Proscar. Patients must be off these
             medicines for more than 4 weeks.
Clinical trial NCT01007084 (phase 2, status: withdrawn)
Conditions: trauma
ICD codes: K08.81, K08.82, O71.9, N48.31, O71.89, G89.11, G89.21
Drugs: propranolol, propranolol er, sugar pills
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Reason stopped: 
    lack of eligible patient recruits/feasibility considerations.
  
Eligibility criteria:

        Inclusion Criteria:

          -  at least one fracture

          -  ages 18-60 yrs

          -  pain score >= 4

          -  speak and read English

        Exclusion Criteria:

          -  gunshot, stab wound, or assault

          -  paraplegia/quadriplegia

          -  pregnancy

          -  psychotic, suicidal, or homicidal

          -  hepatic, kidney failure

          -  clinically unstable or intubated at time of recruitment

          -  hyperthyroidism

          -  propranolol use within the last 6 months

          -  significant bradycardia

          -  cancer (except basal cell)

          -  peripheral vascular disease

          -  heart block > 1 degree

          -  breastfeeding

          -  congestive heart failure
Clinical trial NCT00332176 (phase 2, status: unknown status)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: celgosivir, celgosivir, peginterferon alfa 2b + ribavirin
SMILES: CCCC(=O)O[C@H]1CN2CC[C@H](O)[C@@H]2[C@@H](O)[C@@H]1O, CCCC(=O)O[C@H]1CN2CC[C@H](O)[C@@H]2[C@@H](O)[C@@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  18-65 years of age, inclusive

          -  primary diagnosis of chronic HCV infection, genotype 1

          -  Interferon-based treatment-naïve

          -  Body Mass Index of 18 to 30, inclusive

        Exclusion Criteria:

          -  patients previously treated with Interferon-based therapy

          -  patients with diabetes mellitus
Clinical trial NCT00681876 (phase 2, status: terminated)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: irinotecan, avastin, erbitux
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed locally advanced or metastatic colorectal cancer.

          -  Measurable or evaluable disease according to the Response Evaluation Criteria in Solid
             Tumors (RECIST)

          -  ECOG performance status ≤ 2

          -  Age 18 - 72 years

          -  Patients with de novo refractory disease (progression of disease as best response at
             1st line therapy with FOLFOX/Avastin)

          -  Adequate liver (Bilirubin ≤ 1.5 UNL, SGOT/SGPT ≤ 4 UNL, ALP ≤ 2.5 UNL),renal
             (Creatinine ≤ 1.5 UNL) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function

          -  Patients must be able to understand the nature of this study

          -  Written informed consent

        Exclusion Criteria:

          -  History of serious cardiac disease (unstable angina, congestive heart failure,
             uncontrolled cardiac arrhythmias).

          -  History of myocardial infarction or stroke within 6 months.

          -  Clinically significant peripheral vascular disease.

          -  History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess
             within 28 days prior to Day 0.

          -  Presence of central nervous system or brain mets.

          -  Evidence of bleeding diathesis or coagulopathy.

          -  Patients with known hypersensitive reaction to cetuximab

          -  Blood pressure > 150/100 mmHg.

          -  Pregnant or lactating woman.

          -  Life expectancy < 3 months.

          -  Previous radiotherapy within the last 4 weeks or > 25% of bone marrow.

          -  Metastatic infiltration of the liver >50%.

          -  Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or
             total colectomy.

          -  Active infection requiring antibiotics on Day 1.

          -  Second primary malignancy, except for non-melanoma skin cancer and in situ cervical
             cancer.

          -  Psychiatric illness or social situation that would preclude study compliance.
Clinical trial NCT00193076 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, carboplatin, trastuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

        To be included in this study, you must meet the following criteria:

          -  Locally advanced or metastatic breast cancer

          -  Measurable disease as per RECIST criteria

          -  No prior chemotherapy in the metastatic breast setting

          -  Prior chemotherapy and/or hormonal therapy for early stage breast cancer

          -  Adjuvant Herceptin is allowed

          -  Prior radiation therapy in either the metastatic or early stage setting

          -  Patients may have received any number of hormonal therapies

          -  Age >18 years

          -  Only women are eligible for the study

          -  Able to perform activities of daily living with minimal assistance

          -  Normal organ and bone marrow function

          -  Patients who will be receiving Trastuzumab must have normal heart function

          -  Sign a written informed consent document

        Exclusion Criteria:

        You cannot participate in this study if any of the following apply to you:

          -  Received prior chemotherapy for metastatic breast cancer

          -  Known leptomeningeal carcinomatosis

          -  Uncontrolled brain metastasis

          -  Uncontrolled intercurrent illness

          -  Pregnant or lactating

          -  History of other non-breast cancer malignancy

          -  Received prior chemotherapy for early stage breast cancer within 6 months

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have.
Clinical trial NCT00132730 (phase 2, status: terminated)
Conditions: lung diseases, pulmonary disease, chronic obstructive
ICD codes: J84.115, M05.10, M05.111, M05.112, M05.119, M05.121, M05.122, J44.9, J44.1, J44.0
Drugs: mk-0873 2.5 mg, mk-0873 1.25 mg, mk-0873 0.75 mg, placebo to mk-0873, usual care
SMILES: [O-][N+]1=CC(=CC=C1)C#CC1=CC(=CC=C1)N1C=C(C(=O)NC2CC2)C(=O)C2=CC=CN=C12, [O-][N+]1=CC(=CC=C1)C#CC1=CC(=CC=C1)N1C=C(C(=O)NC2CC2)C(=O)C2=CC=CN=C12, [O-][N+]1=CC(=CC=C1)C#CC1=CC(=CC=C1)N1C=C(C(=O)NC2CC2)C(=O)C2=CC=CN=C12, [O-][N+]1=CC(=CC=C1)C#CC1=CC(=CC=C1)N1C=C(C(=O)NC2CC2)C(=O)C2=CC=CN=C12, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, 40 to 75 years old, with a history consistent with COPD (chronic
             obstructive pulmonary disease)

          -  Lung function tests that meet the requirements of the study

        Exclusion Criteria:

          -  Severe and unstable medical conditions other than COPD (chronic obstructive pulmonary
             disease)

          -  Use of continuous oxygen therapy

          -  Cardiac (heart) arrhythmias

          -  Other lung disease

          -  History of colitis (inflammation of the colon)
Clinical trial NCT00738595 (phase 2, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: evt 302, placebo, evt 302 plus open label nicotine replacement, placebo plus open label nicotine replacement
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)NC1=CC=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Smoker of at least 10 cigarettes daily

          -  Motivated to quit smoking

          -  Reports at least one unsuccessful attempt to quit in the last 2 years

          -  In generally good health

          -  Provides written informed consent to participate in the sudy

        Exclusion Criteria:

          -  Pregnant or nursing females.

          -  Women of child-bearing potential must agree to use acceptable contraceptive
             precautions (contraceptive pill and one barrier method)during the study and for
             2-months thereafter

          -  History of anaphylaxis

          -  History of alcohol or drug abuse

          -  History of or current significant medical or psychiatric disorder

          -  History or presence of cataract or abnormality identified by slit lamp investigation

          -  Use of other MAO inhibitors, pethidine, SSRIs, tricyclic antidepressants,nasal or oral
             decongestants or cold medicines containing ephedrine, pseudoephedrine or other
             sympathomimetics.

          -  Any medicine contraindicated for use with MAO inhibitors.

          -  Have or be a carrier of hepatitis B or c or HIV 1 or 2

          -  Use of tobacco products other than cigarettes

          -  Use of nicotine replacement therapy in the past month

          -  Received an investigational drug in the past 30 days

          -  Previous participation in a study with a MAO-B inhibitor
Clinical trial NCT00541463 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: mk0639, indinavir sulfate / duration of treatment: 48 weeks, comparator: nelfinavir mesylate / duration of treatment: 48 weeks
SMILES: CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12, [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  At least 18 years of age

          -  HIV positive

          -  No active heart disease

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  Unwilling to use birth control or abstinence to prevent pregnancy

          -  Received an investigational drug or vaccine within the past 30 days or is planning to
             receive other investigational study drug/vaccine or interferon while in the study

          -  Plan to receive NNRTIs while in the study

          -  Received therapy which lowers body's ability to fight infection within the past 30
             days or while in the study

          -  Alcohol or substance abuse

          -  Hepatitis